Invivyd (NASDAQ:IVVD – Get Rating) had its price objective lowered by analysts at Morgan Stanley from $3.00 to $2.00 in a research report issued on Tuesday, Benzinga reports. The brokerage presently has an "underweight" rating on the stock. Morgan Stanley's target price would suggest a potential downside of 1.96% from the company's previous close.

Invivyd Stock Performance

Shares of NASDAQ IVVD opened at $2.04 on Tuesday. The company's 50-day moving average is $2.00. Invivyd has a 52-week low of $1.42 and a 52-week high of $12.11. The stock has a market cap of $222.32 million, a P/E ratio of -0.79 and a beta of -0.50.

Invivyd (NASDAQ:IVVD – Get Rating) last issued its quarterly earnings data on Thursday, November 10th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.04. As a group, equities research analysts forecast that Invivyd will post -2.18 EPS for the current fiscal year.

About Invivyd

Invivyd, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease.

Further Reading

• Get a free copy of the StockNews.com research report on Invivyd (IVVD)
• Intuit Is About To Make a Move, But Which Way?
• 3 Late January Earnings Plays With Pop Potential
• Low-Priced Stocks Still Paying Dividends
• Why is the Chipotle Stock Price Surging This Week?
• Is the Northrop Grumman Selloff an Opportunity?

Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.